参考文献/References:
[1]Jeon YL,Kim MH,Lee WI,et al.Cystatin C as an early marker of diabetic Nephronpathy in patients with type 2 diabetes[J].Clin Lab,2013,59(11-12):1221-1229. [2]刘红春,苏利沙,赵占正,等.血清胱抑素C评估慢性肾脏病患者肾小球滤过率的应用研究[J].中华检验医学杂志,2014,37(3):184-188. [3]Hamed HM,El-Sherbini SA,Barakat NA,et al.Serum cystatin C is a poor biomarker for diagnosing acute kidney injury in critically-ill children[J].Indian Journal of Critical Care Medicine,2013,17(2):92-98. [4]陶志虎,肖琦,吕冬宁,等.胱抑素C联合氨基末端脑利钠肽前体对维持性血液透析患者心血管事件的预测作用[J].中华肾脏病杂志,2014,30(7):506-511. [5]李治国,张绍武,王春玲.老年支原体肺炎患者胱抑素C及微量白蛋白检测的意义[J]中国老年学杂志,2014,34(12):3458-3459. [6]钟正霞,李正付,裘志成,等.IgA肾病患者血清胱抑素C与肾脏病理变化的关系探讨[J].现代医药卫生,2015(3):398-400. [7]张双元.改变胱抑素C实验参数对检验结果的影响分析[J].中国现代医生,2014,52(10):54-58. [8]Narvaez Sanchez R,Gonzalez L,Salamanca A,et al.Cystatin C could be a replacement to serum creatinine for diagnosing and monitoring kidney function in children[J].Clin Bioche,2008,41(7-8):498-503． [9]Uruska A,Araszkiewicz D,Zozulinska-Ziolkiewicz M,et al.Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes[J].Clin Biochem.2014,47(13-14):1235-1238. [10]Pavlaki A,Printza N,Farmaki E,et al.The role of urinary NGAL and serum cystatin C in assessing the severity of ureteropelvic junction obstruction in infants[J].Pediatric Nephrology,2020(1):163-170. [11]Kim DJ,Kang HS,Choi HS,et a1.Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels[J].Korean Journal of Hepatology,2011(17):130-138. [12]刘宋芳,王述进,杨华,等.胱抑素C在尿清蛋白阴性的2型糖尿病患者中对早期肾病的诊断价值[J].检验医学与临床,2019,16(9):2500-2502. [13]王金霞.血清胱抑素C和β2微球蛋白检测在2型糖尿病肾病早期诊断中的价值[J].现代诊断与治疗,2018,29(18):108-110. [14]周士明.外周血胱抑素C在检测肾功能早期损伤中的研究[D].山东大学,2015. [15]曾庆玫.血清胱抑素C、β2微球蛋白对评估2型糖尿病患者肾脏损伤的意义[D].广西医科大学,2015. [16]张毕明,肖帅,吴意.胱抑素C诊断早期急性肾损伤价值的Meta分析[J].检验医学与临床,2018,15(23):7-9,13. [17]刘海燕,杨文东.血清同型半胱氨酸和胱抑素C水平与冠状动脉病变严重程度的相关性[J].检验医学与临床,2012,9(11):1328-1330. [18]孙思,满建英.血清脂蛋白a胱抑素C视黄醇结合蛋白在2 型糖尿病早期肾损害诊断中的价值[J].实用医技杂志,2017,24(7):748-749. [19]廖玉香,邱森灵,曾海英,等.血清胱抑素C 及尿微量白蛋白联合检测在糖尿病肾病早期诊断的应用[J].实用医技杂志,2017,24(6):645-646. [20]谈玲,李元宽.血清胱抑素Ｃ与视黄醇结合蛋白在糖尿病肾病诊断中的意义[J].检验医学与临床,2017,14(10):1460-1462. [21]Li F,Hu L,Zhao X,et al. The value of cystatin C and urinary and serum neutrophil gelatinase-associated lipocalin during the perioperative period of renal transplantation[J].Transl Androl Urol,2019,8(5):432-441. [22]张凤华.探讨肝病患者胱抑素C测定的临床价值[J].中外医疗,2019,24(8):182-184. [23]莫甲光.血清胱抑素C测定在肾功能损伤中的临床应用[J].标记免疫分析与临床,2015,22(2):159. [24]朱美丽.血清胱抑素C、同型半胱氨酸及C-反应蛋白在糖尿病肾病早期诊断中的价值探讨[J].中国民康医学,2013(14):9-10,29. [25]邓道丽.血清胱抑素C检测在肾功能损伤患者病情诊断中的应用[J].临床医药文献电子杂志,2017(3):132-133. [26]Liyanage PLGC,Lekamwasam S,Weerarathna TP2,et al.Prevalence of normoalbuminuric renal insufficiency and associated clinical factors in adult onset diabetes[J].BMC Nephrol,2018 19(1):200-208． [27]王琦,周艳辉,林珍.原发性高血压患者脉压与血浆同型半胱氨酸、胱抑素C的相关性研究[J].重庆医学,2016,45(9):1269-1270. [28]孙建琦,胡宇宁,汪靖,等.胱抑素C与原发性高血压患者室壁厚度及心功能不全的相关性[J].安徽医学, 2013,34(10):1478-1480. [29]沈逸华,郭腾飞,蔡晓琪,等.轻中度原发性高血压患者血管舒张功能与血清胱抑素C的关系[J].中华高血压杂志,2017(3):56-60. [30]孙继兴,赵刚,杨雅静,等.恶性肿瘤患者血清、胸水、腹水、囊肿液、尿液中胱抑素C和可溶性尿激酶受体水平的测定[J].中国老年学杂志,2011,31(1):498.
相似文献/References:
[1]李 艳.胱抑素C临床检验及对诊断肾脏疾病的临床价值[J].医学信息,2018,31(04):42.[doi:10.3969/j.issn.1006-1959.2018.04.014]
LI Yan.Clinical Test of Cystatin C and its Clinical Value in the Diagnosis of Renal Diseases[J].Medical Information,2018,31(04):42.[doi:10.3969/j.issn.1006-1959.2018.04.014]
[2]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Medical Information,2018,31(04):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[3]熊武芳,杨 娜,肖光军,等.同一厂家两种胱抑素C检测试剂盒的性能验证及其
检测结果的一致性[J].医学信息,2018,31(15):55.[doi:10.3969/j.issn.1006-1959.2018.15.018]
XIONG Wu-fang,YANG Na,XIAO Guang-jun,et al.Performance Verification of Two Cystatin C Test Kits and Consistency of Test Results from the Same Manufacturer[J].Medical Information,2018,31(04):55.[doi:10.3969/j.issn.1006-1959.2018.15.018]
[4]黄秉文.中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J].医学信息,2018,31(22):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
HUANG Bing-wen.Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States[J].Medical Information,2018,31(04):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
[5]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Medical Information,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[6]韩佳妮.参芪地黄汤治疗早期糖尿病肾病的疗效[J].医学信息,2019,32(22):139.[doi:10.3969/j.issn.1006-1959.2019.22.047]
HAN Jia-ni.Effect of Shenqi Dihuang Decoction in Treating Early Diabetic Nephropathy[J].Medical Information,2019,32(04):139.[doi:10.3969/j.issn.1006-1959.2019.22.047]
[7]马 燕,王晓忠,延国威,等.乙肝肝硬化低血钠症患者血清钠、肌酐以及胱抑素C与肾功能损害程度的关系[J].医学信息,2020,33(19):55.[doi:10.3969/j.issn.1006-1959.2020.19.017]
MA Yan,WANG Xiao-zhong,YAN Guo-wei,et al.The Relationship Between Serum Sodium,Creatinine,Cystatin C and the Degree of Renal Damage in Patients with Hepatitis B Liver Cirrhosis and Hyponatremia[J].Medical Information,2020,33(04):55.[doi:10.3969/j.issn.1006-1959.2020.19.017]
[8]左俊荣.特发性膜性肾病的诊断及治疗研究[J].医学信息,2021,34(11):54.[doi:10.3969/j.issn.1006-1959.2021.11.016]
ZUO Jun-rong.Research on the Diagnosis and Treatment of Idiopathic Membranous Nephropathy[J].Medical Information,2021,34(04):54.[doi:10.3969/j.issn.1006-1959.2021.11.016]
[9]段宗宝,肖三法,罗惠群.环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究[J].医学信息,2021,34(23):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
DUAN Zong-bao,XIAO San-fa,LUO Hui-qun.Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy[J].Medical Information,2021,34(04):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
[10]舒霁坤,沈学耕.慢性心力衰竭患者炎症细胞因子水平与心室重构的相关性分析[J].医学信息,2022,35(02):100.[doi:10.3969/j.issn.1006-1959.2022.02.024]
SHU Ji-kun,SHEN Xue-geng.Correlation Between Inflammatory Cytokines and Ventricular Remodelingin Patients with Chronic Heart Failure[J].Medical Information,2022,35(04):100.[doi:10.3969/j.issn.1006-1959.2022.02.024]